AI assessment JBZY becoming OTC current.
"The only hope for this abandoned corporation is some Chinese businessman needing USD."
Conclusion:
Since JBZY has been inactive and made no money since 2021, the costs to regain OTC current status are significantly lower than for an active company with complex financials. The company can likely file minimal financial disclosures reflecting inactivity, reducing accounting and audit expenses. However, legal and OTC fees remain, so a realistic budget to make JBZY OTC current again would be approximately $17,500 to $47,000.
Conclusion:
JBZY’s no-debt status, manageable outstanding shares, existing OTC listing, and inactive shell profile make it a strong candidate for a reverse merger. It fits the typical profile of a public shell company sought by private companies aiming to go public quickly and cost-effectively without a traditional IPO.
However, success depends on JBZY’s ability to:
Update and maintain regulatory compliance and filings.
Manage the change of control process with shareholder approvals.
Possibly conduct corporate actions (e.g., reverse splits) to meet OTC market standards.
Navigate regulatory scrutiny with transparent disclosures and governance.
If these conditions are met, JBZY could serve as an effective vehicle for a reverse merger transaction.
Market Data 
Markets 
AI
